路易体病AT(N)亚组中的脑脊液突触生物标志物
本研究回顾性检测了28名非神经退行性神经疾病认知正常对照和161名路易体病或阿尔茨海默病患者的脑脊液AD核心及突触/神经轴索生物标志物。路易体病A+T+亚组的突触和神经轴索损伤标志物高于A-T-亚组,且β-突触核蛋白鉴别准确性最高(AUC 0.938)。路易体病A+T+与AD组各标志物水平无差异。
要点
- 路易体病A+T+亚组脑脊液β-突触核蛋白、α-突触核蛋白、SNAP-25、神经颗粒素和NfL水平高于A-T-亚组(p<0.01)。
- β-突触核蛋白鉴别路易体病A+T+与A-T-的AUC为0.938(95%CI 0.884-0.991)。
- 路易体病A+T+与AD组各生物标志物水平无差异,提示存在AD共病理的路易体病具有独特的突触功能障碍特征。
核心结论
- 路易体病A+T+和AD患者脑脊液突触与神经轴索生物标志物水平显著高于路易体病A-T-和对照组。
- 伴有AT(N)分类中AD共病理的路易体病患者表现出与其他路易体病病例不同的突触功能障碍特征。
研究设计与样本
- 回顾性研究,纳入28名认知正常非神经退行性神经疾病对照和161名路易体病或AD患者(AD-MCI 30例、AD-dem 30例)。
- 检测脑脊液AD核心标志物(Aβ42/40比值、磷酸化tau蛋白、总tau蛋白)及突触标志物(β-突触核蛋白、α-突触核蛋白、SNAP-25、神经颗粒素)和神经轴索蛋白(NfL)。
- 按临床和AT(N)亚组比较脑脊液生物标志物水平。
主要发现
- 路易体病组(n=101,年龄67.2±7.8岁,女性27.7%)与对照组(年龄64.8±8.6岁,女性39.3%)的β-突触核蛋白、α-突触核蛋白、SNAP-25、神经颗粒素和NfL水平无差异。
- AD组(AD-MCI n=30,AD-dem n=30,年龄72.3±6.0岁,女性63.3%)上述标志物水平高于路易体病组和对照组(所有比较p<0.001)。
- 路易体病A+T+亚组突触和神经轴索变性标志物水平高于A-T-亚组(所有比较p<0.01),β-突触核蛋白鉴别两组AUC为0.938(95%CI 0.884-0.991)。
- 路易体病A+T+亚组脑脊液β-突触核蛋白(p=0.0021)、α-突触核蛋白(p=0.0099)和SNAP-25(p=0.013)浓度高于A+T-亚组,后者突触标志物水平在正常范围内。
- 路易体病T-亚组患者脑脊液α-突触核蛋白较对照组显著降低(p=0.0448);路易体病A+T+与AD组任何标志物水平均无差异。
关键数值与推荐
- β-突触核蛋白鉴别路易体病A+T+与A-T-的AUC为0.938(95%CI 0.884-0.991)。
- 路易体病A+T+与A-T-比较:β-突触核蛋白p=0.0021,α-突触核蛋白p=0.0099,SNAP-25 p=0.013。
- 路易体病T-亚组与对照组比较α-突触核蛋白p=0.0448。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients with Lewy body disease (LBD) often show a co-occurring Alzheimer disease (AD) pathology. CSF biomarkers allow the detection in vivo of AD-related pathologic hallmarks included in the amyloid-tau-neurodegeneration (AT(N)) classification system. Here, we aimed to investigate whether CSF biomarkers of synaptic and neuroaxonal damage are correlated with the presence of AD copathology in LBD and can be useful to differentiate patients with LBD with different AT(N) profiles. METHODS: We retrospectively measured CSF levels of AD core biomarkers (Aβ42/40 ratio, phosphorylated tau protein, and total tau protein) and of synaptic (β-synuclein, α-synuclein, synaptosomal-associated protein 25 [SNAP-25], and neurogranin) and neuroaxonal proteins (neurofilament light chain [NfL]) in 28 cognitively unimpaired participants with nondegenerative neurologic conditions and 161 participants with a diagnosis of either LBD or AD (at both mild cognitive impairment, AD-MCI, and dementia stages, AD-dem). We compared CSF biomarker levels in clinical and AT(N)-based subgroups. RESULTS: CSF β-synuclein, α-synuclein, SNAP-25, neurogranin, and NfL levels did not differ between LBD (n = 101, age 67.2 ± 7.8 years, 27.7% females) and controls (age 64.8 ± 8.6 years, 39.3% females) and were increased in AD (AD-MCI: n = 30, AD-dem: n = 30, age 72.3 ± 6.0 years, 63.3% females) compared with both groups (p < 0.001 for all comparisons). In LBD, we found increased levels of synaptic and neuroaxonal degeneration biomarkers in patients with A+T+ (LBD/A+T+) than with A-T- profiles (LBD/A-T-) (p < 0.01 for all), and β-synuclein showed the highest discriminative accuracy between the 2 groups (area under the curve 0.938, 95% CI 0.884-0.991). CSF β-synuclein (p = 0.0021), α-synuclein (p = 0.0099), and SNAP-25 concentrations (p = 0.013) were also higher in LBD/A+T+ than in LBD/A+T- cases, which had synaptic biomarker levels within the normal range. CSF α-synuclein was significantly decreased only in patients with LBD with T- profiles compared with controls (p = 0.0448). Moreover, LBD/A+T+ and AD cases did not differ in any biomarker level. DISCUSSION: LBD/A+T+ and AD cases showed significantly increased CSF levels of synaptic and neuroaxonal biomarkers compared with LBD/A-T- and control subjects. Patients with LBD and AT(N)-based AD copathology showed, thus, a distinct signature of synaptic dysfunction from other LBD cases. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that CSF levels of β-synuclein, α-synuclein, SNAP-25, neurogranin, and NfL are higher in patients with AD than in patients with LBD.
引用
- Barba L, Abu-Rumeileh S, Halbgebauer S, et al. CSF Synaptic Biomarkers in AT(N)-Based Subgroups of Lewy Body Disease. Neurology. 2023. PMID: 37188538. doi:10.1212/WNL.0000000000207371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。